Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients

(MedPage Today) -- Durable responses were seen when axicabtagene ciloleucel (axi-cel; Yescarta) was administered as a first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), according to findings from the phase II ZUMA-12 trial...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news